Blog

Antonio Calles: Cardiotoxicity of osimertinib is real

Antonio Calles/ruberinternacional.es

Feb 6, 2025, 15:29

Antonio Calles: Cardiotoxicity of osimertinib is real

Antonio Calles, Head of the Lung Cancer Unit at Hospital Ruber Internacional, shared an article Minjung Bak and colleagues authored on X:

“Cardiotoxicity of osimertinib is real. In this Korean study, osimertinib-related cardiotoxicity was 4.7%, including 3.4% requiring cardiologic intervention. Age and previous heart conditions identified. Implications for long-lasting treatment.”

Antonio Calles

The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population

Authors: Minjung Bak et al.

Antonio Calles: Cardiotoxicity of osimertinib is real

Antonio Calles cancer Eun Kyoung Kim Hyukjin Park Hyun Ae Jung Jihoon Kim Jin Seok Ahn Jinhyun Cho Minjung Bak Myung-Ju Ahn Nuri Lee OncoDaily Oncology Sang-Chol Lee Se-Hoon Lee Sehhoon Park Seung Woo Park Sung-A Chang Sung-Ji Park

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer

Daiichi Sankyo's and Astrazeneca's press release on ENHERTU®: Latest Updates from DESTINY-Gastric04 trial

13-year-old Cancer Survivor Sworn in as a Secret Service agent by President Trump - The White House

The European Parliament Intergroup on Cancer and Rare Diseases has been set in motion - ECO